Market Research Logo

Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Pipeline Review, H2 2018

Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Pipeline Review, H2 2018

Summary

Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Re


Introduction
Global Markets Direct Report Coverage
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Overview
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Companies Involved in Therapeutics Development
Aeterna Zentaris Inc
Allergan Plc
AstraZeneca Plc
Daiichi Sankyo Co Ltd
Millendo Therapeutics Inc
Oxeia Biopharmaceuticals Inc
Pfizer Inc
RaQualia Pharma Inc
Zeria Pharmaceutical Co Ltd
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Drug Profiles
anamorelin hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZ-12861903 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EXT-400 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EXT-405 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HM-03 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HM-04 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ibutamoren mesylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
livoletide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
macimorelin acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OXE-103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptide to Agonize GHSR for Acute Ischemic Stroke, Acute Radiation Syndrome and Sepsis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-05190457 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
relamorelin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RQ-00433412 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize Ghrelin Receptor for Obesity - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize Ghrelin Receptor for Obesity - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize GHSR for Cachexia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Modulate GHSR for Chronic Kidney Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ulimorelin hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Z-505 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Dormant Products
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Discontinued Products
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Product Development Milestones
Featured News & Press Releases
Jun 28, 2018: URI drug study produces ‘promising therapy’ for alcohol abuse
Mar 05, 2018: Aeterna Zentaris Provides Update on Previously Disclosed Class Action Lawsuit
Mar 05, 2018: Lyric Completes Enrollment in Phase 2 PROMOTE Study of LP101 (Ulimorelin) in Enteral Feeding Intolerance
Jan 23, 2018: Lyric Pharmaceuticals Presents Data at ASPEN Conference on the Incidence of Enteral Feeding Intolerance in the ICU
Jan 17, 2018: Lyric Pharma Granted FDA Fast Track Designation for Lead Product Ulimorelin for Enteral Feeding Intolerance
Dec 20, 2017: Aeterna Zentaris Announces FDA Approval of Macrilen (macimorelin) for Diagnosis of Adult Growth Hormone Deficiency
Nov 27, 2017: Aeterna Zentaris Marketing Authorization Application for Macrilen (macimorelin) for Evaluation of Adult Growth Hormone Deficiency Accepted by European Medicines Agency
Sep 15, 2017: Refusal of the marketing authorisation for Adlumiz (anamorelin hydrochloride)
Sep 06, 2017: Oxeia Biopharmaceuticals Announces Appointment Of Dr. Michael Wyand As Chief Executive Officer
Aug 23, 2017: Richard Sherman, NFL All-Pro, Joins Oxeia Biopharmaceuticals Advisory Board
Jul 18, 2017: NDA for Macrilen for the Evaluation of Growth Hormone Deficiency in Adults Granted December 30, 2017 PDUFA Date
Jun 30, 2017: Aeterna Zentaris Resubmits NDA for Macrilen for the Evaluation of Growth Hormone Deficiency in Adults
Jun 19, 2017: Ammonett Pharma Granted Orphan Drug Designation From the U.S. FDA for Ibutamoren Mesylate (MK-0677) for Treatment of Growth Hormone Deficiency
May 25, 2017: Ammonett Pharma Receives Notice of Allowance of U.S. Patent for Oratrope Related to Detecting and Treating Growth Hormone Deficiency
May 23, 2017: Ammonett Pharma Receives Positive Opinion from European Orphan Medicinal Products Committee for MK-0677 for Treatment of Pediatric Growth Hormone Deficiency
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Aeterna Zentaris Inc, H2 2018
Pipeline by Allergan Plc, H2 2018
Pipeline by AstraZeneca Plc, H2 2018
Pipeline by Daiichi Sankyo Co Ltd, H2 2018
Pipeline by Millendo Therapeutics Inc, H2 2018
Pipeline by Oxeia Biopharmaceuticals Inc, H2 2018
Pipeline by Pfizer Inc, H2 2018
Pipeline by RaQualia Pharma Inc, H2 2018
Pipeline by Zeria Pharmaceutical Co Ltd, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd..1), H2 2018
Dormant Products, H2 2018 (Contd..2), H2 2018
Discontinued Products, H2 2018
List of Figures
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report